ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 224 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,562,919 | -13.3% | 110,924 | +58.8% | 0.01% | -13.3% |
| Q1 2021 | $1,802,698 | -56.4% | 69,872 | -9.7% | 0.02% | -54.5% |
| Q4 2020 | $4,136,147 | +1609.2% | 77,369 | +1217.1% | 0.03% | +1000.0% |
| Q3 2020 | $242,000 | -1.6% | 5,874 | +15.8% | 0.00% | 0.0% |
| Q2 2020 | $246,000 | +12.3% | 5,074 | -4.3% | 0.00% | 0.0% |
| Q1 2020 | $219,000 | -80.2% | 5,301 | -82.8% | 0.00% | -66.7% |
| Q3 2019 | $1,108,000 | -42.4% | 30,780 | -66.8% | 0.01% | -25.0% |
| Q3 2018 | $1,925,000 | -73.7% | 92,758 | -61.9% | 0.01% | -64.7% |
| Q4 2017 | $7,326,000 | -45.2% | 243,300 | -31.4% | 0.03% | -61.8% |
| Q3 2017 | $13,368,000 | +133.3% | 354,900 | +72.8% | 0.09% | +134.2% |
| Q2 2017 | $5,729,000 | -70.2% | 205,400 | -63.2% | 0.04% | -73.2% |
| Q1 2017 | $19,203,000 | +2031.3% | 558,567 | +1686.8% | 0.14% | +2740.0% |
| Q4 2016 | $901,000 | +5.6% | 31,261 | +16.5% | 0.01% | 0.0% |
| Q3 2016 | $853,000 | -20.9% | 26,837 | -19.3% | 0.01% | 0.0% |
| Q2 2016 | $1,079,000 | -66.6% | 33,240 | -71.2% | 0.01% | -73.7% |
| Q1 2016 | $3,227,000 | +252.3% | 115,400 | +349.0% | 0.02% | +280.0% |
| Q4 2015 | $916,000 | -37.1% | 25,700 | -41.7% | 0.01% | -44.4% |
| Q3 2015 | $1,457,000 | -7.4% | 44,053 | +17.2% | 0.01% | +12.5% |
| Q2 2015 | $1,574,000 | +120.8% | 37,582 | +71.6% | 0.01% | +100.0% |
| Q1 2015 | $713,000 | +72.6% | 21,900 | +68.5% | 0.00% | +100.0% |
| Q4 2014 | $413,000 | +11.3% | 13,000 | -13.3% | 0.00% | -33.3% |
| Q3 2014 | $371,000 | -25.5% | 15,000 | -31.9% | 0.00% | -25.0% |
| Q2 2014 | $498,000 | -8.1% | 22,020 | -1.1% | 0.00% | -20.0% |
| Q1 2014 | $542,000 | -93.0% | 22,258 | -92.8% | 0.01% | -89.8% |
| Q4 2013 | $7,702,000 | -0.6% | 308,205 | +9.2% | 0.05% | -35.5% |
| Q3 2013 | $7,751,000 | +48.5% | 282,200 | -1.8% | 0.08% | +35.7% |
| Q2 2013 | $5,219,000 | – | 287,504 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |